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Abstract
Currently there are no FDA approved targeted therapies for Triple Negative Breast
Cancer (TNBC). Ongoing clinical trials for TNBC have focused primarily on targeting the
epithelial cancer cells. However, targeted delivery of cytotoxic payloads to the nontransformed tumor associated-endothelium can prove to be an alternate approach that
is currently unexplored. The present study is supported by recent findings on elevated
expression of stromal galectin-1 in clinical samples of TNBC and our ongoing findings
on stromal targeting of radiation induced galectin-1 by the anginex-conjugated arseniccisplatin loaded liposomes using a novel murine tumor model. We demonstrate inhibition
of tumor growth and metastasis in response to the multimodal nanotherapeutic
strategy using a TNBC model with orthotopic tumors originating from 3D tumor tissue
analogs (TTA) comprised of tumor cells, endothelial cells and fibroblasts. The ‘rigorous’
combined treatment regimen of radiation and targeted liposomes is also shown to be
well tolerated. More importantly, the results presented provide a means to exploit
clinically relevant radiation dose for concurrent receptor mediated enhanced delivery
of chemotherapy while limiting overall toxicity. The proposed study is significant as it
falls in line with developing combinatorial therapeutic approaches for stroma-directed
tumor targeting using tumor models that have an appropriate representation of the
TNBC microenvironment.

Introduction

More aggressive than other forms of breast cancer, TNBC
presents an early, truculent visceral metastases, a short
life expectancy with poor prognosis and few effective
treatment options [3, 7–9]. The standard of care for TNBC
patients’ remains to be traditional chemotherapy, surgery
and radiation. Unlike the receptor driven breast cancers,
the oncologists do not have any FDA approved targeted
therapies from the existing drug arsenal for advanced
stage of TNBC that presents an average progression
free survival of 12 months, which is far less than the
other subtypes of BC. Identifying specific targets for
more effective and promising therapies for treatment of

Breast cancer (BC) is the second leading cause of
death in women. Of those diagnosed with breast cancer,
15–20% are classified as triple negative breast cancer
(TNBC) [1, 2] prevalent in women with African American
ethnicity and younger age [3–5]. TNBC is a heterogeneous
subtype, that is histopathologically diagnosed based on the
characteristics of “triple negativity” defined by the lack
of expression or overexpression of the “three receptors’:
estrogen receptor (ER), progesterone receptor (PR) and
the epidermal growth factor receptor type 2 (HER2) [6].
www.impactjournals.com/oncotarget
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TNBC has therefore become a major clinical challenge.
An improved understanding of the biology of TNBC has
led to the discovery of therapeutic targets for TNBC,
such as the Notch signaling pathway (RO-4929097) [10],
Wnt/b-catenin pathway (Salinomycin) [11], DNA repair
pathways (PARP1 inhibitors: Iniparib, Olaparib) [12, 13],
Overexpressed epidermal growth factor (EGFR inhibitors:
Gefltinib, cetuximab) [14, 15], P13/Akt/mammalian
target of rapamycin (mTOR) activation (mTOR inhibitors
(Everolimus) [16] and TGF-β signaling pathway
(TGFBR1 inhibitor: LY2157299) [17]. However, the
molecular heterogeneity of TNBC [18, 19] may explain
for the marginal benefits in clinical trials with these
targeted therapies that are majorly focused on targeting
single pathways in the epithelial cancer cells, a critical
contributor to the TNBC heterogeneity [20]. The limited
success of the molecularly targeted therapies in TNBC
thus, highlights the ongoing importance for cytotoxic
therapy and the need for ‘think-out of the box’ approaches
to develop novel treatment strategies augmenting the
current treatment options for TNBC.
Therapeutic options to target the tumor stroma
are limited with the most exploited exception being
bevacizumab (Avastin, Roche), a monoclonal antibody
that targets vascular endothelial growth factor (VEGF)
and inhibits tumor angiogenesis [21]. However, its use
in the treatment of TNBC has not been encouraging
and therefore was restricted by the FDA in late 2011
for subsequent use in the treatment of metastatic breast
cancer [22]. A carbohydrate binding protein, galectin-1,
which plays a pivotal role in tumor growth and cancer
progression including invasion, angiogenesis and
metastasis is a propitious alternative for stromal targeting
of the non-transformed tumor associated-endothelium.
Studies, including our own, have demonstrated the
potential of galectin-1 as a therapeutic target by
identifying the overexpression of galectin-1 in various
human cancers and enrichment in tumor stroma [23, 24].
In addition, we have reported a further induction of
galectin-1 expression in tumor stroma as a response to
radiation therapy, suggesting that targeting galectin-1 may
synergize with radiation therapy [23–25]. A number of
novel compounds and approaches to block galectin-1 or its
activity are currently being evaluated [23]. The synthetic
antiangiogenic peptide, anginex, has been shown to bind
specifically to the galectin-1 receptor and delay the tumor
growth [26–28]. Anginex is an antiangiogenic 33 amino
acid beta sheet peptide [29–31] that specifically binds and
inhibits the function of galectin-1 receptor [27, 32–34].
While unable to completely block tumor growth, anginex
can serve as an excellent ligand for targeted delivery of
liposomal cytotoxic payloads to the tumor endothelium.
However, developing nanotherapeutic regimens that
target the tumor stroma implicitly demand reliable tumor
models that replicate the stromal characteristics of the
human cancer. Using a murine in vitro/in vivo TNBC
tumor model system with galectin-1 enriched stroma we
www.impactjournals.com/oncotarget

have reported that conjugation of anginex to liposomes
enables preferential targeting of the unique mix of dual
chemotherapy released at the irradiated tumor endothelium
in a controlled manner over time, beyond that expected
from enhanced tumor permeability and retention [25].
This novel therapeutic approach is designed to destabilize
the tumor microenvironment which sensitizes and primes
the tumor cells for cell death, maximizing the therapeutic
gain of the antitumor strategy in selective and effective
inhibition of tumor growth and metastasis in contrast
to conventional systemic approaches. In this study we
establish the overexpression of galectin-1 in the TNBC
stroma using the murine tumor model system with an
appropriate representation of the tumor microenvironment
developed in our laboratory we have investigated the
therapeutic efficacy as well as the biocompatibility of
the radiation enhanced galectin-1 targeting with anginex
conjugated arsenic trioxide (ATO) and cisplatin loaded
liposomes to the TNBC microenvironment.

RESULTS
Similarity in the expression profile of galectin-1
to VEGF-A in ductal carcinoma of the breast
indicate it’s potential as a candidate for stromadirected molecular targeting
The primary objective of targeted drug nanoparticle
delivery is to isolate the disease in vivo against the
background of the normal functioning tissue without
disrupting or altering usual physiologic processes. The
task of developing such a receptor-targeted nanoparticle
delivery is particularly challenging as it depends upon
identifying a biomarker or disease characteristic that can
be ‘targeted’ to achieve the goal. There is compelling
evidence for galectin-1 as an important protein in
cancer biology that is enriched in the tumor- associated
neovascular endothelium [24, 27, 32, 33]. We also
explored the data from The Human Protein Atlas for the
expression of galectin-1 in ductal carcinomas of women
between 27–40 years of age (Figure 1A). Statistical
evaluation of the immunohistochemistry revealed
significantly increased expression of galectin-1 in
tumor tissues as compared to the normal breast tissues
(Figure 1B). Enlarged images of the ductal carcinoma
tissue sections (20×) demonstrated the stromal enrichment
of galectin-1 (Figure 1B). Furthermore, this difference
in the expression of galectin-1 between normal versus
the ductal carcinoma tissues of patients was found to
be comparable to the expression of vascular endothelial
growth factor (VEGF-A) in the same or similar tissues.
VEGF-A, a multifunctional cytokine secreted by human
tumors, is implicated with poor prognosis in breast cancer
[35, 36]. One of the major challenges in developing a
molecular targeted therapy is in identifying a biomarker
significantly overexpressed in the tumor tissue, not just
41560
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in comparison to the corresponding normal tissue but in
tissue of other normal organs. The data from the Human
Protein Atlas in Figure 2 demonstrates that while galectin-1
is expressed in organs other than the breast, the quantitation
of representative images indicated the galectin-1 expression
to be notably higher in the tumor tissues in comparison to
the other normal tissues (Figure 2).

significant staining of the myoepithelial or adipose tissue
(black arrows) (Figure 3A and 3C). The median H score for
Galectin-1 for benign tissue was 63.12. In contrast, tumor
staining was more uniform with a more intense membrane
staining pattern in both the ductal and lobular units. The
pronounced staining in the tumors was in the intervening
myoepithelial and stromal tissue, with a median H Score
of 186.1 (Figure 3A–3B). This suggests a significant
difference in the level of galectin-1 expression between
benign and tumor tissue that could be manipulated as a
target for tumor specific drug delivery. Histopathology
of the tumor and benign tissue sections from the TNBC
patient samples was evidenced by the hematoxylin and
eosin (H&E) staining (Supplementary Figure S1).

Elevated expression of stromal galectin-1 in
clinical samples of TNBC
Galectin-1 staining in normal breast tissue was
identified using immunohistochemical analysis, and there
appeared to be a low level of membrane staining primarily
involving the normal ductal and lobular units, with no

Figure 1: Elevated levels of galectin-1 in human tissues of ductal carcinoma compared to the normal breast tissue
resemble the expression profile of VEGF-A. (A) Spot images of human breast cancer (ductal carcinoma) and normal breast tissues

1 mm in diameter of women 27–40 years in age stained with galectin-1 antibody (Sigma) [Upper panel] and VEGF antibody (Santa Cruz
Biotech.) [Lower panel]. (B) Quantitation of image scans (Aperioscope) demonstrating higher % of positive staining for both galectin-1 and
VEGF-A in ductal carcinoma versus normal breast tissue with *p < 0.0001 and **p < 0.05 respectively (mean ± SE; n = 3 samples/group).
(C) 20X magnification of ductal carcinoma sections in (A) immunoprobed for galectin-1 demonstrating its stromal enrichment (Brown).
Tumor cells stain blue (DAPI). Data were provided by the human protein atlas database. Scale bar = 100 μm.

www.impactjournals.com/oncotarget
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Figure 2: The differential expression profile of galectin-1 in various human tissues compared to ductal carcinoma. (A)

Representative spot images of six types of tissues 1 mm in diameter as indicated were probed (Brown) for the expression of galectin-1
(Sigma) were compared to tumor tissue of ductal carcinoma stained for galectin-1. Data were provided by the human protein atlas database
(http://www.proteinatlas.org/). (B) Galectin-1 staining was quantitated by APERIO® ImageScope and scored using the H-score approach
that combines the pixel intensity with the percentage of tissue as described in the methods and graphically represented. (N = 3, *p < 0.005
or **p < 0.05, for tissues from the tumor compared to that from other organs).

Figure 3: Galectin-1 overexpression in clinical samples of triple negative breast cancer (TNBC) patients. (A)
Immunohistochemistry of six cases of TNBC matched with the corresponding normal breast tissues for galectin-1. The tissue sections
were stained with anti-galectin-1 antibody (sigma) and counterstained with Hematoxylin and Eosin (Supplementary Figure S1) at 100X
magnification. Scale bar = 25 μm (B) Galectin-1 staining in each histological section of benign and tumor tissues of the six TNBC patients
was scored using the H-score approach as described in the methods and graphically represented. The percentage of tissue stained was
quantitated by APERIO® ImageScope (N = 6, *p = 0.0002 for tumor tissue compared to the benign tissue). (C) Representative images
of benign and primary tumor tissue probed for galectin-1. While the tumor cells stained weakly (blue/light brown), the tumor associated
stroma stained strongly for galectin-1 (brown) in the tumor tissue. The myoepithelial cells/clusters and ductal/lobular units in the benign
breast tissue also stained strongly for galectin-1 (black arrows) but the staining was restricted to distinct foci. Scale bar = 50 μm.
www.impactjournals.com/oncotarget
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Radiation exposure augments the expression
of galectin-1 in the murine TNBC model
developed from orthotopic implant of 3D ‘Tumor
tissue analog’ (TTA) in nude mice that better
represents the malignant stroma

constitutively phosphorylated mutant p53 observed in
several cancer cell types, escapes the Murine Double
Minute 2 protein (MDM2) and stabilizes in the tumor
cells [39, 40], enabling them to evade cell death. However,
the transient activation of wild type p53 in response to
pharmacological stimulus or stress triggers a flexible
cascade of gene expression that determines whether a cell
type will undergo cell cycle arrest or programmed cell
death [41–43]. Proteolytic cleavage of PARP by caspases
is a universal phenomenon observed during programmed
cell death induced by a variety of apoptotic stimuli
including those that trigger activation of p53 [44–46]. It
has thus been used in this study as a readout for evaluation
of apoptotic cell death. Our results demonstrate that while
the p53 defective MDA-MB-231 cells despite displaying
profuse constitutive phosphorylation at the serine
15 residue, show no decrease in intact PARP, the functional
p53 in HUVEC undergo phosphorylation by 24 hr with
an associated decrease or complete absence of full length
PARP in response to either drug treatments, indicating
that the sensitivity of different cell types to the two drugs
is associated with the on activation/phosphorylation of
p53. Based on this differential sensitivity of cell types
contributing to the tumor formation, the nanotherapeutic
strategy augmented by radiation exposure is so designed to
target cytotoxic payloads of ATO and cisplatin that while
increasing the dual drug concentration at the tumor site,
will also create a microenvironment pernicious for survival
of tumor cells. Efforts are now underway to delineate the
p53-dependent and independent cell death/ damage via
the intercellular crosstalk in response galectin-1 targeting
in the tumor and its microenvironment utilizing our 3D
TNBC tumor model [25].

We have demonstrated the usefulness of the 3D
TNBC model in in vivo setting by implantation of the
TTA in the mammary fat pad of nude mice [24, 25]. This
preclinical tumor model incorporates aspects of the tumor
microenvironment and the neovascular architecture,
critical for evaluating nanoparticles and stroma-directed
molecular targeting. Our studies have also elucidated the
radiation-induced galectin-1 surge to be more pronounced
in the murine TNBC model developed from orthotopic
implants of TTA comprised of tumor cells, endothelial
cells and fibroblasts than the orthotopic implants of tumor
cell only–spheroids [25]. Using the same murine TNBC
model in this study we compare the galectin-1 expression
between benign breast, tumor and irradiated tumor tissue
originating from TTA implants in the mammary fat pad
of nude mice (Figure 4A and Supplementary Figure S2).
The H-scores for galectin-1 expression were found to
be significantly higher in the irradiated tumor tissue in
comparison to the non-irradiated or benign breast tissue
(Figure 4B).

Sensitivity to ATO and cisplatin cytotoxicity in
cell types is associated with p53 phosphorylation
FDA approved, Metal-based drugs such as ATO
and cisplatin administered at high concentrations for
effective tumor cell killing often present dose-limiting side
effects. However, their encapsulation in nanoliposomes
bound to receptors for specific cell targeting allows
for their prudent use in improvement of anti-cancer
efficacy. Molecular profiling with antibody arrays and
the ingenuity pathway analysis in our earlier studies
indicate the enhanced activation/phosphorylation of
proteins associated with the apoptotic or stress signaling
in response to radiation enhanced targeting of arsenic and
cisplatin loaded liposomes in 3D murine TTA and their
orthotopic implants to occur via phosphorylation of the
functional p53 in endothelial cells [25]. In this study have
designed an experiment to demonstrate a similar effect in
the sensitivity of two different human cell types to arsenic
and cisplatin. MDA-MB-231, a typical human TNBC cell
line, fails to achieve an IC50 at cisplatin concentration
of 30 µM [18]. Similar studies with ATO demonstrate
a 12–15 µM IC50 for MDA-MB-231 cells [37, 38].
Figure 5 demonstrates a significant decrease in the
expression of intact poly ADP-ribose polymerase (PARP)
(116 kda), indicative of more cell death, in endothelial
cells (HUVEC) but not the MDA-MB-231 TNBC cells
incubated at much lower concentrations of cisplatin
(20 µM) and ATO (5 µM). Literature suggests that the
www.impactjournals.com/oncotarget

Radiation-enhanced therapeutic targeting of
galectin-1 in the murine TNBC model developed
from orthotopic implant of 3D TTA in nude mice
The complex organization of tumor microen
vironment has been shown to be a critical component
of response to therapeutic interventions in cancer
[31, 47–50]. The field of cancer therapy is therefore in
the midst of a major paradigm shift from an approach
primarily focused on tumor cell killing to strategies that
also targets the tumor microenvironment [51]. Preclinical
tumor models that more appropriately represent the
tumor and the malignant stroma such as the 3D TNBC
model that we have developed from TTA implants in
athymic nude mice enhance the ability to study devise
target-based therapeutic interventions. Our recent studies
demonstrate targeting of irradiated tumor endothelial cells
via radiation-induced stromal enrichment of Galectin-1
using Anginex conjugated liposomes encapsulating ATO
and cisplatin. The platinum-arsenic loaded liposomes are
very stable and are designed to release the drug only when
internalized and processed through receptor-mediated
41563
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endocytosis. Figure 6 illustrates the radiation enhanced
tumor-targeting of anginex conjugated dual drug-(ATO
and cisplatin) loaded liposomes using the murine tumor
model that better represents the microenvironment and
structural characteristics of TNBC.

treatment regimen for ~3 weeks. Further, initiating the
nanotherapeutic treatment regimen when the orthotopic
tumors are ~200 mm3 (was also based on the rationale
and our previous studies to ensure the formation of the
tumor-associated stroma for targeting in the murine TNBC
model [25]. While non-conjugated liposomes and anginex
conjugated liposomes inhibited growth of irradiated
and non-irradiated mammary tumors respectively by
~40%, tumor growth was significantly reduced by ~80%
in irradiated tumors treated with anginex-conjugated
liposomes. The tumor growth in the non-irradiated mice
treated with non-conjugated liposomes was reduced only
~20% (Figure 7A–7B). Combined treatment of radiation
and targeted nanoparticles was well tolerated by the
mice with no significant difference in body weight when
compared to radiation control (Figure 7C).

The combinatorial nanotherapeutic strategy
inhibits tumor growth and metastasis in the
murine tumor model for TNBC
The therapeutic targeting of anginex-conjugated
(4 mg ATO/kg, 2.5 mg cisplatin /kg), non-conjugated (4
mg ATO/kg, 2.5 mg cisplatin /kg) was evaluated in nonirradiated and irradiated tumors (~200 mm3) originating
from TTA implants in the mammary fat pad of athymic
nude female mice. Empty liposomes administered to
mice bearing irradiated tumors served as control. Our
initial observations of TTA implanted orthotopically in
the mammary fat pad of mice resulted in large tumors
(~1500 mm3) with aggressive metastasis to the lungs.
The rapid progression of the disease required the mice
to be sacrificed within 20–24 days [25]. Expecting a
similar outcome in tumor bearing mice when treated with
vehicle alone we opted to leave this treatment group from
the experiment designed to understand the response to a

The combinatorial nanotherapuetic strategy
inhibits metastasis to the lung and results in
increased accumulation of arsenic and cisplatin
in the tumor tissue
Consistent with enhanced tumor efficacy, our
study on invasion of the disease to distant organs
revealed that metastasis to the lung was much reduced

Figure 4: Radiation augmented galectin-1 expression in orthotopic tumors originating from TTA. (A) Representative

images of immunohistochemistry for galectin-1 in benign breast tissue (BT), tumor tissue (TT) and irradiated tumor tissue (IT) originating
from orthotopic implants of TTA in mice 72 hours post-radiation exposure of 2 Gy. (B) Galectin-1 staining was quantitated by APERIO®
ImageScope and scored using the H-score approach as described in the methods and graphically represented. N = 3/group, *p < 0.0003 for
TT vs IT, BT vs. IT and BT vs TT.

Figure 5: Sensitivity of HUVECs but not tumor cells to cisplatin and ATO is associated with phosphorylation of
p53. MDA-MB-231 tumor cells and HUVECs were treated with 20 µM and 10 µM cisplatin and ATO respectively. Treatment with both

drugs caused decrease in PARP expression and serine 15 phosphorylation of p53 in HUVECs but relatively no change in both in the
MDA- MB- 231 cells.
www.impactjournals.com/oncotarget
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in the irradiated animals treated with the targeted
liposomes (Figure 8A– 8B).In our previous study we
have demonstrated an increased uptake of the targeted
nanoparticle with higher accumulation of arsenic and
cisplatin 24 hr post treatment by the irradiated tumor
tissue in the orthotopic implants of the TTA in nude mice
[25]. These results established the radiation-enhanced
targeting of stromal galectin-1 by the anginex-conjugated
nanoparticles in the murine tumor model for TNBC.
In this study, using the same TNBC model we have
quantified the arsenic and cisplatin accumulation in the
tumor tissue at the completion of the treatment regimen by
ICP-MS. While the uptake of both arsenic and cisplatin in
the irradiated tumors of mice at the end of the treatment
regimen with the anginex-conjugated nanoparticles is
higher than with non-conjugated nanoparticles, it is not
as significant (Figure 8C–8D). It is now a universally
accepted fact that all nanoscale particulate carriers
including targeted and passively targeted liposomes
are distributed to the target cells via the same passive
distribution mechanism, by means of the enhanced
permeability and retention effect [52]. An increased uptake
of targeted liposomes by the diseased tissue, occurs as a
consequence of the increased receptor-mediated uptake

of liposomes, containing the entrapped drug, by the target
cell [53]. The significant increase in arsenic and cisplatin
accumulation in the irradiated tumor tissue after a single
dose of the anginex-conjugated nanoparticle is possibly
owing to the relatively faster clearance of the non-targeted
nanoparticles from the intratumoral space [25]. However,
repeated dosing as in this study may have increased
the accumulation of the non-conjugated nanoparticles
without affecting the drug uptake by the target cell and
the subsequent improvement in therapeutic response.
We also observe higher accumulation of cisplatin in the
tumor tissue (9 μg/g tissue or higher) at the completion
of the treatment regimen of radiation in conjunction
with targeted or non-targeted nanoparticles (Figure 8C).
Cisplatin undergoes aquation to form [Pt(NH3)2Cl(OH2)]+
and [Pt(NH3)2(OH2)2]2+ once inside the cell, intercalating
between the DNA strands forming the cisplatin-DNA
adducts [54]. The half-life of free ATO on the other hand
falls between 10–48 hr (Agency for Toxic Substance &
Disease Registry, 2007) and therefore we observed a
notably lower concentration of arsenic in tumor tissues
(1–2 μg/g tissue) post-treatment (Figure 8D).
The tissue residence of arsenic and cisplatin at
the end of the study in different organs of the treated

Figure 6: A Schematic representation of radiation enhanced nanotherapeutic targeting in the orthotopic tumor
originating from Tumor tissue analogs (TTA) recreating TNBC and its microenvironment.
www.impactjournals.com/oncotarget
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mice by ICP-MS showed a similar trend as observed in
the tumor tissues of higher accumulation of cisplatin in
comparison to arsenic (Supplementary Figure S3). The
kidney and liver were sites with maximum residence
of arsenic and cisplatin. ICP-MS analysis of the brain
tissue revealed minimum accumulation of the two drugs.
Restricted entry of most biomolecules by the blood brain
barrier [55] and the glomerular kidney or sinusoidal
liver capillaries forming the fenestrated vascular bed
are the possible reasons for the respective low and high
acquisition of arsenic and cisplatin in these organs [56].
Systemic toxicity during the treatments, was assessed
by H&E staining of tissue sections from different organs
of the experimental mice (Supplementary Figure S4).
The H&E images indicated that all major organs after
treatments maintained their typical structural phenotypes

and did not exhibit appreciable microscopic lesions,
further confirming the minimal side effects and acceptable
biocompatibility.

Discussion
Compelling evidence gathered over recent decades
indicate galectin-1, to be amongst the unique repertoire
of proteins overexpressed across a spectrum of human
cancers. These include breast [57], colon [58], lung
[59], head & neck [60], ovarian [61] and prostrate [62]
carcinomas in addition to gliomas [63], Kaposi’s sarcoma
[64], myeloproliferative neoplasia [65] and Hodgkin
lymphoma [66]. The overexpressed galectin-1 is localized
both in the stroma surrounding the tumor cells and in the
cancer associated endothelial cells [67–69]. Here we report

Figure 7: The combinatorial nanotherapeutic strategy inhibits tumor growth with no significant change in body
weight in the murine TNBC model. (A) Representative images of mammary tumors post treatment in female athymic nude mice with

orthotopic implants of TTA. 14 days after surgical implantation of TTA in the mammary fat pad, mice were randomized into five treatment
groups: Radiation + empty liposomes (3 Gy + vehicle), non-conjugated (ATO/cisplatin loaded) liposomes (Non-conjugated), Radiation
+non-conjugated liposomes (3 Gy + Non-Conjugated), anginex-conjugated (ATO/cisplatin loaded) targeted liposomes (Ax-conjugated),
Radiation + anginex-conjugated targeted liposomes (3 Gy + Ax-Conjugated). Agents were delivered 2 hrs post-radiation twice at an interval
of 24 hr via tail vein injection and the regimen was repeated three times with a gap of 4 days as indicated. (B) Graphical representation of
tumor growth in mice with orthotopic xenografts of TTA. (C) No significant weight loss was observed in any treatment group compared
with radiation + vehicle-treated mice. Results indicated as mean ± SD (N = 3 mice/group). *p < 0.005 (vehicle vs non-conjugated and
vehicle vs Ax-conjugated, non-conjugated vs ax-conjugated nanoparticle treatment with and without radiation).
www.impactjournals.com/oncotarget
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an elevated expression of galectin-1 in clinical samples
from TNBC patients and data collected from the Human
protein atlas on ductal carcinoma in women between the
ages of 27–40 years (Figures 1 and 3). The galectin-1
expression profile in tumor and benign tissue sections
of ductal carcinomas was also comparable to VEGF, a
multifunctional cytokine, most clinically exploited for
vascular targeting in tumors (Figure 1). To develop a tumor
specific galectin-1 targeting delivery system that enhances
the effectiveness of the nanotherapeutics, it was essential
for us to assess the differential expression of galectin-1 in
normal and tumor tissue. In accordance with the results
from studies on other cancer associated malignancies, we
also found, galectin-1 to be consistently overexpressed
in the tumor-associated stroma of TNBC patients with
significantly lower expression in benign breast and normal
tissues from other organs (Figures 1–3). The recruitment
of endothelial cells to form new blood vessel is an
important step in the development, invasion and metastatic
colonization of proliferative neoplasms such as the TNBC
[70]. The targeting of transformed tumor cells has several

limitations owing to their inherent drug resistance and
highly heterogeneous malignant cell population [47–49].
While most chemotherapy is capable of killing tumor
cells efficiently, it lacks the ability for selective targeting
[71, 72]. Conversely, many anti-angiogenic agents, while
not able to control tumor growth, possess the ability to
selectively target the location and process of tumor blood
vessel formation [73, 74]. The current study capitalizes
on the radiation enhanced targeting of the antiangiogenic,
anginex peptide to the galectin-1 enriched tumor
microvasculature [24, 75] and the existing technique of
liposomal encapsulation of chemotherapy to design a
novel therapeutic approach for selective and effective
inhibition of tumor growth and metastasis in TNBC.
Ongoing efforts in the laboratory are directed to perform
in-depth investigations for understanding the mechanistic
underpinnings of radiation-augmented galectin-1 surge
in the 3D TTA that enable enhanced binding of anginexconjugated targeted liposomes.
While there are no specialized guidelines for
TNBC treatment, single or multi-agent chemotherapy

Figure 8: The combinatorial nanotherapeutic strategy results in inhibition of lung metastasis with increase in Arsenic
and cisplatin accumulation in the murine tumor model for TNBC. (A) Representative images metastatic lesions in diseased

lungs post treatment in female athymic nude mice with orthotopic implants of TTA randomized in three treatment groups: Radiation +
empty liposomes (3 Gy + vehicle), Radiation +non-conjugated (ATO/cisplatin loaded) liposomes (3 Gy + Non-Conjugated), Radiation
+ anginex-conjugated (ATO/cisplatin loaded) targeted liposomes (3 Gy + Ax-Conjugated). Agents were delivered 2 hrs post-radiation
twice at an interval of 24 hr via tail vein injection and the regimen was repeated three times with a gap of 4 days as indicated. (B) Graphic
representation of lung metastasis in mice bearing tumors originating from TTA implants. Results indicated as mean ± SD (N = 3 mice/
group).*p < 0.05 (vehicle vs non-conjugated and Ax-conjugated nanoparticle treatment). Athymic nude mice with orthotopic implants of
TTA after completion of the 6 treatments in the treatment regimen were sacrificed and tumor tissues were analyzed for arsenic (C) and
cisplatin (D) by ICP-MS. Results indicated as mean ± SD (N = 3 mice/group) with *p < 0.001 for for arsenic cisplatin acquisition at the end
of the study in mice with irradiated tumors treated with vehicle vs non-conjugated and vehicle vs Ax-conjugated nanoparticle. The #p < 0.05
was also significant for cisplatin but not arsenic uptake in irradiated mice treated with non-conjugated vs ax-conjugated nanoparticles.

www.impactjournals.com/oncotarget
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weight-loss and lack of observable signs of toxicity in
organ histology associated with liposomal treatment in
conjunction with radiation is attributed to the stability of
the drug payload in physiological and acidic conditions,
and so despite typical liposomal accumulation in the liver
and other tissues there is minimal toxicity (Figure 7D).
Since treatment options available for TNBC are limited,
the ability of such a novel nanotherapeutic system to
deliver combined therapy while limiting toxicity has the
potential to improve survival outcome in TNBC patients
and accelerate drug development.

continues to remain the mainstay in the treatment of
TNBC patients. Owing to concerns for significant toxicity,
radiation when used is delivered sequentially following
systemic chemotherapy. The benefits of radiation therapy
in locoregional control and recurrence in breast cancer
with improved survival [76] has sparked a recent interest
to analyze the role of radiation in breast conserved
therapy and locoregional recurrence in TNBC [77–79].
Interestingly, our studies have revealed a further induction
of the stromal galectin-1 in response to radiation exposure
in 2D, 3D and various preclinical tumor models [24, 25]
and (Figure 4), indicating the possibility of combining
radiation with targeted nanochemotherapy and reduced
side effects. Furthermore, though ATO and cisplatin are
identified as a synergistic drug combination in lung and
squamous cell carcinomas [80, 81], the use of metalbased cytotoxic agents in standard clinical treatments of
tumors is currently limited because (i) they cause acute
systemic toxicity and cannot be administered at effective
concentrations, (ii) are unstable in circulation and (iii)
are subject to multiple mechanisms of drug resistance.
The co-encapsulation of these drugs in nanocarriers
overcome most of these challenges. When bound to
receptors for specific cell targeting these nanovesicles are
at a further advantage, as they are taken up by receptormediated endocytosis, thereby avoiding drug efflux by
P-glycoprotein and overcoming drug resistance [82].
Evidence supports a major subgroup of TNBC
originating from epithelial cells is genomically unstable
with mutated p53 [83]. Our study using a p53 defective
human epithelial TNBC cell line, MDA-MB-231 and a
p53 functional human endothelial cell type, HUVEC,
indicates the sensitivity to ATO and cisplatin in
different human cell types to be regulated by activation/
phosphorylation of p53 phosphorylation (Figure 5) and is
similar to the effect observed in our in vitro/in vivo 3D
murine TNBC models [25]. This led us to design a two
pronged active targeting strategy augmented by radiation
exposure (Figure 6): that while increasing the dual drug
concentration at the tumor site, creates a microenvironment
unconducive for tumor cell survival. ATO encapsulated in
nanovesicles was expected to facilitate effective tumortargeted delivery by causing vascular damage [84, 85]
and overcoming resistance of tumor cells to conventional
cisplatin chemotherapy. The controlled release of cisplatin
from the tumor endothelium targeted liposomes was
expected to further enhance the therapeutic efficacy
of the drug delivery system by simulating the effect of
low-dose metronomic chemotherapy [86]. In this study
we investigate the therapeutic outcome of radiation
enhanced tumor-targeting of nanosized ATO and cisplatin
chemotherapy to the galectin-1 enriched malignant stroma.
Data obtained from this study suggests the means to
exploit clinically relevant radiation dose for concurrent
receptor mediated enhanced delivery of chemotherapy
while limiting overall toxicity (Figure 7). The minimal
www.impactjournals.com/oncotarget

MATERIALS AND METHODS
Cell lines and culture
4T1-mCherry is a red fluorescent protein-expressing
murine metastatic mammary carcinoma cell line that closely
mimics the triple negative subtype of human breast cancer
[87]; was a kind gift from Dr. D. D. Schlaepfer (University
of California, San Diego, CA). 2H11, murine tumor
endothelial cell line [88], and C166-GFP, a murine green
fluorescent protein-expressing endothelial cell line, were
purchased from ATCC (Manassas, VA). Murine embryonic
fibroblasts (MEF) were a kind gift from Dr. V. Rangnekar
(University of Kentucky, Lexington, KY). The cell lines
were routinely cultured in high glucose DMEM containing
10% (v/v) fetal bovine serum and 100 IU/mL penicillin,
100 IU/mL streptomycin at 37°C, 5% CO2, and 95%.

Chemicals and reagents
Arsenic [Arsenic (III) oxide] and Cisplatin [cisDiamineplatinum (II) dichloride] were purchased from
Sigma-Aldrich, Inc. (St. Louis, MO). Anginex peptide
was purchased from AAPPTEC (Louisville, KY). The
antibodies, galectin-1 (Sigma #HPA000646) and (R&D
AF-1152) were used for immunohistochemistry of
clinical and murine tumor tissue samples respectively.
The antibodies, p53 phospho (ser15) (#9284) and poly
(ADP-ribose) polymerase [PARP] (#9532) for western
immunoblotting were purchased from Cell Signaling
Technology. Lipids used for liposome preparation were
purchased from Avanti Polar Lipids (Alabaster, Al).

Tumor tissue analogs (TTA) for orthotopic
implant in nude mice
4T1-mcherry tumor cells, C166-GFP endothelial
cells and murine embryonic fibroblasts (MEF) were
used to generated single or multicell type 3D cultures
in “hanging drops” of media (Dulbecco modified Eagle
medium with 10% fetal bovine serum and antibiotic
mix) as previously described [50]. Briefly, single a cell
suspension of 4T1-mcherry cells, C166-GFP cells and
MEF cells in equal proportion (3000 cells/20 μL) was
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In orthotopic tumors originating from TTA in
athymic nude mice

dispensed on the inside of the lid of each well of a 48-well
cell culture plate (Greiner Cellstar, BioExpress, Kaysville,
UT). The growth of TTA was monitored over time until
day 14 in a hanging drop of medium, following which
they were subject to radiation exposure and treatment with
liposomes. The 3D co-cultures/TTA were subsequently
transferred to optically clear Greiner repellent plates for
imaging and analysis of the treatment response over a
period of 8–10 days.

Formalin fixed paraffin embedded tissue was
sectioned at 4-microns and dried overnight at 58°C. Slides
were deparaffinized and hydrated stepwise followed by
heat-induced epitope retrieval (HIER) in high pH antigen
retrieval solution (Dako) at 110°C for 20 minutes using
a Biocare Medical Decloaking Chamber. Slides were
incubated in Galectin-1 antibody (R&D AF-1152) diluted
at 1:50 for one hour at room temperature followed by
incubation with polymer bound anti-goat secondary for
30 minutes (Vector Laboratories Immpress kit). Staining
was visualized by incubation with 3, 3′-diaminobenzidine
(DAB) chromogen (Dako, CA) for 5 minutes and slides
were lightly counterstained with hematoxylin.

Animals
All animal procedures were approved by the
University of Kentucky Animal Institutional Care and
Use Committee (IACUC). Female, athymic nude mice
(Crl:NU(Ncr)-Foxn1nu) obtained from Charles River
(6–12 weeks old, 20–22 gm) were purchased from
Harlan’s Laboratories (Haslett, MI). All experimental mice
were housed in sterile environmental conditions of the
University of Kentucky’s Division of Laboratory Animal
Resources (DLAR) and provided sterile food and water
ad libitum.

Evaluation and quantification of
immunohistochemistry
All slides were digitalized on an APERIO®
ScanScope (Leica Biosystems) and were evaluated on
an APERIO® ImageScope (Leica Biosystems)using the
positive pixel counting algorithm, which scores the stains
as negative, weak-positive, medium, and strong. This
algorithm also measures the percentage of positivity by
area and the average intensity of positive staining. HScore
for each case of benign and tumor tissue sample from
TNBC patient, based on the percentage and intensity of
staining was determined. HScore takes into consideration
the intensity of the staining and the percentage of
positive cells per the formula: HScore = 1 × (% light
staining) + 2 × (% moderate staining) + 3 × (% strong
staining). HScores range from 0 to 300 [89].

Orthotopic breast cancer model
Mice were anesthetized with isoflurane (1–4%
vaporizer) or Ketamine/Xylazine, IP, 100/10 mg/kg
respectively. Two TTA generated from 3D cultures of
tumor cells, endothelial cells and fibroblasts as described
in [25] were subcutaneously implanted by a small incision
(2–4 mm) bilaterally into the fat pad of the 3rd mammary
gland and sutured with tissue adhesive (3M VetBond,
St. Paul, MN) Tumor growth was recorded by caliper
measurement after a recovery period of 1–2 days. Mice
were euthanized at study endpoint by isoflurane overdose.
Tumor tissues and lungs were excised for further analysis.

Hematoxylin and eosin staining and imaging

Immunohistochemistry for galectin-1 expression

Hematoxylin and eosin (H&E) staining was
performed by staining the cryostat sections of TES
with Harris hematoxylin (aluminum potassium sulfate,
hematoxylin, absolute alcohol, mercuric oxide, and
glacial acetic acid) followed by 1% acid alcohol and,
subsequently, 1% eosin. Images were taken at 40X
magnification using a Nikon Ti E upright microscope
with a Cool SNAP HQ2 CCD camera (Tokyo, Japan) and
processed with NIS-Elements basic research software.

In clinical samples of tumor and benign tissue
fromTNBC patients
Six cases of triple negative breast cancer from
formalin fixed surgical archives of the University of
Kentucky were selected and 4-micron thick sections were
cut from each and dried overnight at 58°C. Slides were
deparaffinized and hydrated stepwise followed by heatinduced epitope retrieval (HIER) in high pH antigen
retrieval solution (Dako) at 110°C for 20 minutes using
a Biocare Medical Decloaking Chamber. Slides were
incubated in Galectin-1 antibody (Sigma #HPA000646)
diluted at 1:400 for 30 minutes at room temperature
followed by incubation with polymer bound anti-rabbit
secondary for 30 minutes (Dako Envision+). Staining
was visualized by incubation with 3, 3′-diaminobenzidine
(DAB) chromogen (Dako, CA) for 3 minutes and slides
were lightly counterstained with hematoxylin.
www.impactjournals.com/oncotarget

Tumor/Cell X−Ray irradiation
Radiation exposure was given using the Varian
TrueBeam System (Varian medical systems, Palo
Alto, CA) X-Ray machine set at a radiation dose rate
1.018 ± 0.10 Gy/ min at 150 kV and 6.6 mA. Typical
radiation exposure in all experiments was at 3 Gy. Mice were
anesthetized with Ketamine/Xylazine, IP, 100/10 mg/ kg, and
radiation was administered with a custom cut lead shielding
covering the animal, except for the tumor-bearing region.
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Whole cell lysates and immunoblot analysis

an alkyne-containing lipid molecule, creating alkynemodified reactive liposomes. The alkyne liposomes and
the azide Anginex are then cross-linked using a coppercatalyzed alkyne-azide cycloaddition “click” reaction [25].
The resulting liposomes are stable at 4°C for 6 months
without aggregating, precipitating or loosing therapeutic
potency. Drug release from the liposomes is triggered by
thiol-containing compounds, such as glutathione.

Whole cell extracts were prepared by suspending
cells in 0.25 ml of lysis buffer (25 mM HEPES, pH 7.5,
0.5% 498 J Mol Med (2013) 91:497–506 sodium
deoxycholate, 5 mM EDTA, 5 mM dithiothreitol,
20 mM glycerophosphate, 1 mM Na3VO4, 50 mM
NaF, 1% Triton X-100, 20 μg/ml aprotinin, 50 μg/ ml
leupeptin, 10 μM pepstatin, 1 μM okadaic acid, and
1 mM phenylmethylsulfonyl fluoride). The lysates were
incubated at 4°C with gentle agitation on a rocker plate
(Mini Mixer, Benchmark Research Products, NY) for 1 h
and cell debris was removed by centrifugation (15 min at
12,000 × g). The protein concentration in the supernatant
was determined usingthe bicinchoninic acid (BCA) protein
assay kit (Pierce). Immunoblotting was performed using
30 µg of protein/lane and standard polyvinylidene fluoride
membrane transfer followed by probing with the respective
antibody and chemiluminescent detection of bands.

Tail vein injection
The animals were anesthetized as described above.
DID
[Dioctadecyl-tetramethylindodicarbocyanine]
labeled liposomes (4 mg ATO/kg, 2.5 mg cisplatin/kg)
were administered at a volume of 150–200 µl with a
27 G needle in the lateral tail vein of mice bearing the
subcutaneous mammary fat pad tumors ~200 mm3 in size.

Inductively coupled plasma-mass spectrometry
The quantitative analysis of Platinum and Arsenic
in tumor tissue samples of tumors and other organs was
accomplished via ICP-MS of acid digested samples using
a Thermo XSeries II ICP-MS (Thermo-Fisher Scientific,
Waltham, MA) as described [91]. Briefly, Platinum and
Arsenic quantification in tumor tissues was accomplished
via ICP-MS of acid digested samples using a Thermo
XSeries II ICP-MS (Thermo-Fisher Scientific, Waltham,
MA). Specifically, samples were prepared by adding
200 µL of nitric acid (HNO3, 70%, Aristar Plus Grade,
BDH) and 50 µL of hydrochloric acid (30%, Aristar Plus
Grade, BDH) to pre-weighed tissues and incubated at 80°C
for 8 hrs for complete sample digestion. Multi-element
internal standard (Inorganic Ventures, Christiansburg, VA)
and filtered deionized H2O (18.2 MΩ·cm) were added,
producing a final ICP-MS sample of 4% (v/v) HNO3, 1%
HCl, and 5 ng/mL multi-element internal standard.

Synthesis and characterization of Anginexconjugated liposomes
The untargeted liposomes were synthesized using
the aquo-cisplatin concentration gradient as previously
described [90]. In these studies, untargeted liposomes
were comprised of disteroylphospatidyl choline,
cholesterol, and distearoylphosphatidyl ethanolaminemPEG2000 at a molar ratio of 0.5/0.46/0.04, respectively,
with additional 0.1 mol% DiD (1,1′-Dioctadecyl-3,3,3′,3′Tetramethylindodicarbocyanine Perchlorate) fluorescent
dye (Life Technology). The lipids were produced at large
scale using techniques described previously [91, 92]
Anginex-azide was synthesized by modifying the protein
at the N-terminus using azide-dPEG4-NHS (Quanta
Biodesign). Alkyne functional lipids were synthesized
and inserted into pre-formed liposomes as previously
described [92]. Anginex-azide was reacted with the
alkyne-liposomes at 25-fold molar excess compared to
concentration of liposomes. Unconjugated anginex was
removed by tangential flow filtration. Phospholipid,
arsenic and platinum concentration was determined by
ICP-OES and particle size was measured by dynamic
light scattering (Malvern Zetasizer). Nanob were
characterized by ICP-OES, using a matrix of 3% nitric
acid, 2% acetic acid and water. Details are provided in
the methods described earlier [25]. Briefly, the liposomes
were diluted into matrix, then analysed by ICP-OES.
Size was determined by dynamic light scattering in the
Keck Biophysics Core Facility, using a 514 nm laser
equipped with a Brookhaven BI-200 goniometer and
BI-9000 high speed correlator. The modification of the
liposome formulation with anginex to target galectin-1
overexpressed on irradiated endothelial cell surface occurs
in three convergent steps. First, the anginex is modified
with a heterobifunctional crosslinker containing an azide
group. Next, drug-loaded liposomes are modified with
www.impactjournals.com/oncotarget

Statistical analysis
Data are summarized as mean ± SD for each
experimental group. Two-sample t-test or analysis of
variance was employed for two-group and multiple group
comparisons, respectively, with contrast generated from
the ANOVA model to perform pairwise comparisons.
Paired t-test was employed for comparison of Galectin-1
H-score for paired normal and tumor samples. Finally,
linear mixed model was employed for comparison
of tumor volume over time. Statistical analysis was
performed using SAS version 9.4.
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